• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

BK090081 Letter

Blood Bank Computer Systems, Inc.
Attention: Ms. Elizabeth Simon
1002 15th St. SW, Suite 120
Auburn, WA  98001-6502

Re:
Product:
Date Received:
Classification:
Device Code:
BK090081
BBCS Hospital Interface Application (BBCSH), H 1.0.0
December 23, 2009
Unclassified
MMH

Dear Ms. Simon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 835-4709 or (301) 827-1800 or at its Internet address: http://www.fda.gov/cber/smlbus.htm.

Sincerely yours,

/signature/

Richard J. Davey, M.D.
Director
Division of Blood Applications
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Enclosure


Indications for Use

510(k) Number: BK090081

Device Name: BBCS Hospital Interface Application (BBCSH), H 1.0.0

Indications For Use:

Patient Order Processing (420) is a critical function used by the Transfusion Laboratory Technician to record orders as they are received by either the Transfusion Services or Reference Laboratory Departments. Patient orders are generated for product and supplies, or for reference testing requests. This function enhances the critical process of reviewing product suitability prior to release for transfusion, electronic crossmatch processing, and complete documentation and audit trail required to support a paperless laboratory environment. In addition, this function will allow for the rebalancing of workflow between processing locations, departments, or technicians.

This function includes the ability to receive electronic orders that are transmitted in HL7 messages received by the BBCS Hospital Interface Application (sold as a separate product). These orders are placed into their own queue. A staff member must monitor the queue and load the orders into the BBCS Primary application for normal processing.